Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement

2 months ago 18

Soumya Eswaran

Tue, January 27, 2026 astatine 6:46 AM CST 3 min read

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 capitalist letter. A transcript of the aforesaid tin beryllium downloaded here. U.S. equity markets experienced a 4th shaped by optimism astir imaginable monetary easing and caution related to economical maturation and valuations. Early gains were driven by beardown AI-related net and the US Federal Reserve’s complaint chopped successful October. However, marketplace sentiment cooled aboriginal successful the 4th owed to mixed signals from the Fed regarding aboriginal policy. Despite this moderation, the 4th contributed positively to robust yearly results, with ample caps rising 17.4% for the twelvemonth and 2.4% successful the quarter, portion tiny caps gained 12.8% for the twelvemonth and 2.2% successful the quarter. Value stocks outperformed growth, returning 3.3% versus 1.2% for the quarter. Market factors and assemblage effects were mixed successful the quarter. Against this backdrop, the Fund delivered a instrumentality of -0.39% (net) successful the quarter, underperforming the Russell 2500 Growth Index’s 0.33% return. As the marketplace heads into 2026, the steadfast is intimately watching the factors that whitethorn impact marketplace returns, including monetary argumentation changes with a caller Fed Chair and the sustainability of AI investments owed to precocious valuations among hyperscalers. The steadfast continues to absorption connected high-quality businesses with beardown competitory advantages, coagulated equilibrium sheets, and wide sustainable net growth. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, Meridian Growth Fund highlighted Exact Sciences Corporation (NASDAQ:EXAS) 1 of its starring contributors. Exact Sciences Corporation (NASDAQ:EXAS) provides crab screening and diagnostic trial products. On January 26, 2026, Exact Sciences Corporation (NASDAQ:EXAS) banal closed astatine $102.51 per share. One-month instrumentality of Exact Sciences Corporation (NASDAQ:EXAS) was 0.60%, and its shares gained 85.00% of their worth implicit the past 52 weeks. Exact Sciences Corporation (NASDAQ:EXAS) has a marketplace capitalization of $19.468 billion.

Meridian Growth Fund stated the pursuing regarding Exact Sciences Corporation (NASDAQ:EXAS) successful its 4th fourth 2025 capitalist letter:

"Exact Sciences Corporation (NASDAQ:EXAS) is simply a crab diagnostics institution champion known for Cologuard, its at-home screening trial for colorectal cancer. The banal initially roseate during the 4th connected signs of reinvigorated maturation and the instauration of a caller trial that drove gross higher. Performance was further boosted successful November erstwhile Abbott announced plans to get Exact Sciences astatine a important premium."